{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:33:47Z","timestamp":1774362827779,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lercanidipine hydrochloride is a third\u2010generation dihydropyridine calcium channel blocker used to treat mild\u2010to\u2010moderate hypertension. The aim of this study is to compare the pharmacokinetic characteristics of lercanidipine hydrochloride tablets (10\u00a0mg) in healthy Chinese volunteers after oral administration under fasting conditions with those of a reference formulation, and to evaluate the bioequivalence and safety of the two formulations. A validated liquid chromatography\u2010tandem mass spectrometry method was established to determine the plasma concentration of lercanidipine. Phoenix WinNonlin software (version 7.0) was used to calculate pharmacokinetic parameters based on plasma drug concentration\u2013time data. The geometric mean ratios and 90% confidence intervals of C\n                    <jats:sub>max<\/jats:sub>\n                    , AUC\n                    <jats:sub>0\u2013t<\/jats:sub>\n                    , and AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    for the test formulation relative to the reference formulation were 110.37% (99.96%\u2013121.86%), 106.81% (99.65%\u2013114.49%), and 106.91% (99.86%\u2013114.45%), respectively, all within the range of 80.00%\u2013125.00%. The test formulation met the bioequivalence acceptance criteria and was well tolerated by healthy Chinese volunteers under fasting conditions.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70045","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:22:21Z","timestamp":1773012141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and Bioequivalence Evaluation of Two Lercanidipine Hydrochloride Tablets in Healthy Chinese Volunteers"],"prefix":"10.1002","volume":"15","author":[{"given":"Biao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology  Xianning P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecology Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology  Xianning P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangliang","family":"Gan","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology  Xianning P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Zhan","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology  Xianning P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.19590"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-024-01622-w"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21710"},{"issue":"3","key":"e_1_2_10_5_1","first-page":"155","article-title":"Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist","volume":"52","author":"Klotz U","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363220-00013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199729002-00002"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060050-00009"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.7.1043"},{"issue":"3","key":"e_1_2_10_10_1","first-page":"173","article-title":"Lercanidipine in hypertension","volume":"1","author":"Borghi C","year":"2005","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"44","article-title":"Formulation and characterization of lercanidipine HCL nanoparticles as fast\u2010dissolving sublingual film","volume":"63","author":"Alsafar ZA","year":"2025","journal-title":"Acta Pharm Sin"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H299"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1215-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9406-x"},{"key":"e_1_2_10_15_1","volume-title":"Product Specific Bioequivalence Guidance. Version 1","author":"Saudi Food and Drug Authority","year":"2022"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.05.013"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00132580-200111000-00008"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.960073"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/js9702168"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:48:51Z","timestamp":1774360131000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpdd.70045"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70045","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2026-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70045"}}